Agilent Technologies (A) Buy, Sell or Hold

Agilent Technologies (A)

Agilent Technologies (A) is covered by Stockchase stock experts. Read their latest opinions, ratings and top picks below.

167.78

+1.10 (0.66%)

as of Oct 2, 2026, 8:00:00 pm Market Open.

6 watching

COMMENT

They report today. Last quarter was a bad miss. They need to tell a good story about pharma.

Wealthica Track your Stocks in your Watch List

BUY

Is up 55% from its April lows. They just reported a strong quarter with 7% organic growth. The business is turning around, helped by re-shoring in life sciences, plus the rise of some medicine that require more hardware to produce. The FDA is less disruptive as expected. The life sciences sector looks attractive.

BUY

Shares popped over 2% after reporting a solid quarter last Wednesday .

BUY ON WEAKNESS

It just affirmed its forecast of 5-7% annual revenue growth and steady operating margin expansion. Trades at only 22x 2025 PE.

PAST TOP PICK

(A Top Pick Nov 24/22, Down 29%)

Sector has been impacted with economic slow down after Covid-19. Believes healthcare sector will be strong in the long term. Lab tools in high demand globally. Will continue to own shares. Well managed company.

TOP PICK

Consumables for labs. Green energy and pharmaceuticals creating all sorts of demand. Last quarter had 17% organic growth, pretty impressive. Guiding to 5-6% organic growth going forward. Underutilized balance sheet could be flexed for acquisitions. Growing dividend. Yield is 0.58%. (Analysts’ price target is $158.56)

BUY

It's been marching up for the last 16 months, doubling since the start of Covid. A lot of this rise came from Covid testing. Yesterday, they reported a top- and bottom-line beat, as revenues grew 26% YOY, driven by their pharma, chemical and energy businesses. He loves it. Amid sector rotations in the past year, this kept rising steadily.

PAST TOP PICK

(A Top Pick Jun 03/20, Up 55%) Great business. Involved in so many industries with secular growth. Underlevered balance sheet, so they'll be able to take advantage of opportunities.

PAST TOP PICK

(A Top Pick Jun 03/20, Up 48%) They've sold a rising number of consumables as medical schools reopen. They've increased revenue guidance for the year as businesses reopen. The valuation is reasonable. He expects them to buy companies in Asia to add to their growth.

TOP PICK

He likes this for their US dividend fund. They will benefit from the urgency to build labs to find a vaccine for COVID-19. An interesting market to be involved in. The space is very oligopolistic and the the company owns a 20% marketshare. Its balance sheet is under-levered he feels and a large amount of recurring revenue to replace lab components. Yield 0.79% (Analysts’ price target is $87.72)

BUY

Re-engineered itself to focus on its test measurement and instrument business. Very broad product line in that space. Moved manufacturing offshore. Really a play on R&D rather than the economy. If you want exposure nanotechnology, optics, Intermaxtic biotechnology, etc. this company has products going into all those areas.

TOP PICK

8.5% yield growth. They like the focus on Alberta. The company mainly has two businesses; one is trucking and the other is moving oil service equipment. Pay out ratio is around 65%. Lots of room for distribution increases. No debt on the balance sheet. Risks could be commodity prices or a slow down in the Alberta economy.( which he does not see happening) Paid $24-30.50.

PAST TOP PICK

(Top Short July 7/05. Down 11%.) It had fallen below the 200 day moving average and every rally that we had, failed to go higher than the 200 which indicated a negative trend. Historically this stock has an up tick at year end, but will then fall again.

WEAK BUY

In a long upward trend line, and you should never buy during this period. Currently, the stock is trying to break up. It could be a trade. If the stock violates the trend lines, be sure to get out.

DON'T BUY

Not a huge fan of this one. They seem to have trouble executing.

Showing 1 to 15 of 32 entries

Most Recent Experts

Bruce Murray

The Murray Wealth Group

Dennis Mitchell, CFA

Sentry Select Capital Corp

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

Jim Cramer - Mad Money

CNBC

Agilent Technologies (A) Frequently Asked Questions

What is Agilent Technologies stock symbol?

Agilent Technologies is a American stock, trading under the symbol A (previously A-N on Stockchase) on the New York Stock Exchange (A). It is usually referred to as NYSE:A or A

Is Agilent Technologies a buy or a sell?

In the last year, 1 stock analyst issued a Buy, Sell, or Hold rating on A (previously A-N on Stockchase). 1 analyst recommended to BUY and 0 analysts recommended to SELL the stock. The latest stock analyst rating is BUY. Read the latest stock experts' ratings for Agilent Technologies.

Is Agilent Technologies a good investment or a top pick?

Agilent Technologies was recommended as a Top Pick by Joe Terranova on 2026-05-27. Read the latest stock experts ratings for Agilent Technologies.

Why is Agilent Technologies stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Agilent Technologies.

Is Agilent Technologies worth watching?

Agilent Technologies is followed by 6 investors on Stockchase and is a trending stock that is worth watching.

What is Agilent Technologies stock price?

On 2026-10-02, Agilent Technologies (A) stock closed at a price of $167.78.

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Agilent Technologies (A)